0 263

Cited 15 times in

The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂

 Sang-Hak Lee  ;  Seok-Min Kang  ;  Sungha Park  ;  Yangsoo Jang  ;  Namsik Chung  ;  Donghoon Choi 
 CLINICAL CARDIOLOGY, Vol.34(2) : 108-112, 2011 
Journal Title
Issue Date
1-Alkyl-2-acetylglycerophosphocholine Esterase/blood* ; 1-Alkyl-2-acetylglycerophosphocholine Esterase/drug effects ; Adult ; Aged ; Anticholesteremic Agents/administration & dosage ; Anticholesteremic Agents/therapeutic use* ; Atorvastatin Calcium ; Azetidines/administration & dosage ; Azetidines/therapeutic use* ; Biomarkers, Pharmacological/blood ; Chemokine CCL2/metabolism ; Cholesterol, LDL/blood ; Drug Therapy, Combination ; Ezetimibe ; Female ; Fibrinogen/metabolism ; Heptanoic Acids/administration & dosage ; Heptanoic Acids/therapeutic use* ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use* ; Hypercholesterolemia/blood ; Hypercholesterolemia/drug therapy* ; Interleukin-6/blood ; Male ; Middle Aged ; Pyrroles/administration & dosage ; Pyrroles/therapeutic use* ; Treatment Outcome ; Young Adult
BACKGROUND: Many of the pleiotropic effects of statins remain to be elucidated. HYPOTHESIS: Different statin regimens with similar lipid-lowering efficacy may have different effects on biomarkers of atherothrombosis including lipoprotein-associated phospholipase A₂ (Lp-PLA₂ ). METHODS: After a 4-week dietary lead-in, 82 hypercholesterolemic patients were randomized to 1 of 2 treatment groups: atorvastatin 20 mg or atorvastatin/ezetimibe 5 mg/5 mg. After 8 weeks of drug treatment, the groups were compared for percent change in lipid parameters, Lp-PLA₂ , interleukin-6 (IL-6), monocyte chemoattractant protein-1, and fibrinogen. RESULTS: Low-density lipoprotein cholesterol (LDL-C) lowering was comparable between the 2 groups (-47% ± 11% and -49% ± 7% in the atorvastatin and combination groups, respectively). Although Lp-PLA₂ was reduced in both groups, the reduction was greater in the atorvastatin group (-42% and -9% [median], respectively, P = 0.03). Although IL-6 was decreased only in the atorvastatin group, IL-6 changes were not significantly different between the 2 groups. The changes in monocyte chemoattractant protein-1 and fibrinogen were similar in each group. CONCLUSIONS: Atorvastatin monotherapy was stronger at reducing plasma Lp-PLA₂ than the low-dose atorvastatin/ezetimibe combination after equivalent LDL-C lowering. This result may provide evidence of potential statin effects beyond the lowering of LDL-C.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Min(강석민) ORCID logo https://orcid.org/0000-0001-9856-9227
Park, Sung Ha(박성하) ORCID logo https://orcid.org/0000-0001-5362-478X
Lee, Sang Hak(이상학) ORCID logo https://orcid.org/0000-0002-4535-3745
Jang, Yang Soo(장양수) ORCID logo https://orcid.org/0000-0002-2169-3112
Chung, Nam Sik(정남식)
Choi, Dong Hoon(최동훈) ORCID logo https://orcid.org/0000-0002-2009-9760
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.